 Amy Franks
Concepts (188)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Education, Pharmacy | 16 | 2024 | 142 | 8.260 |
Why?
| | Schools, Pharmacy | 7 | 2023 | 53 | 3.490 |
Why?
| | Pharmacy | 3 | 2023 | 58 | 2.130 |
Why?
| | Professional-Patient Relations | 3 | 2019 | 47 | 1.300 |
Why?
| | Teaching | 4 | 2024 | 117 | 1.120 |
Why?
| | Educational Measurement | 6 | 2019 | 210 | 1.030 |
Why?
| | Faculty | 5 | 2024 | 66 | 1.020 |
Why?
| | Writing | 3 | 2022 | 37 | 0.910 |
Why?
| | Students, Pharmacy | 4 | 2021 | 121 | 0.910 |
Why?
| | Students | 3 | 2024 | 210 | 0.900 |
Why?
| | Pharmaceutical Services | 2 | 2023 | 55 | 0.880 |
Why?
| | Fellowships and Scholarships | 2 | 2020 | 111 | 0.840 |
Why?
| | Learning | 2 | 2024 | 158 | 0.840 |
Why?
| | Pharmacies | 1 | 2023 | 61 | 0.810 |
Why?
| | Humans | 40 | 2024 | 49827 | 0.730 |
Why?
| | Patient-Centered Care | 2 | 2019 | 128 | 0.710 |
Why?
| | Motivational Interviewing | 2 | 2019 | 32 | 0.700 |
Why?
| | Health Knowledge, Attitudes, Practice | 4 | 2018 | 488 | 0.670 |
Why?
| | Program Development | 2 | 2018 | 166 | 0.610 |
Why?
| | Blood Pressure | 3 | 2012 | 514 | 0.610 |
Why?
| | Probucol | 2 | 2009 | 3 | 0.610 |
Why?
| | Patient Education as Topic | 2 | 2011 | 295 | 0.600 |
Why?
| | Achievement | 1 | 2017 | 39 | 0.590 |
Why?
| | Mass Screening | 2 | 2011 | 351 | 0.580 |
Why?
| | Perception | 1 | 2017 | 116 | 0.560 |
Why?
| | Cross-Sectional Studies | 7 | 2020 | 1541 | 0.540 |
Why?
| | Feedback | 1 | 2016 | 53 | 0.530 |
Why?
| | Tetrazoles | 2 | 2008 | 41 | 0.530 |
Why?
| | Antihypertensive Agents | 2 | 2009 | 115 | 0.520 |
Why?
| | Hypertension | 3 | 2009 | 532 | 0.500 |
Why?
| | Health Personnel | 1 | 2017 | 241 | 0.490 |
Why?
| | Curriculum | 5 | 2019 | 404 | 0.420 |
Why?
| | Community Health Services | 2 | 2011 | 101 | 0.410 |
Why?
| | Energy Drinks | 1 | 2012 | 6 | 0.410 |
Why?
| | Caffeine | 1 | 2012 | 67 | 0.390 |
Why?
| | Platelet Aggregation Inhibitors | 2 | 2012 | 174 | 0.390 |
Why?
| | Faculty, Medical | 2 | 2023 | 90 | 0.380 |
Why?
| | Coronary Disease | 1 | 2011 | 132 | 0.370 |
Why?
| | Cardiovascular Diseases | 3 | 2012 | 440 | 0.360 |
Why?
| | Female | 16 | 2024 | 26329 | 0.350 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2009 | 102 | 0.330 |
Why?
| | Cardiovascular System | 1 | 2009 | 49 | 0.330 |
Why?
| | Biphenyl Compounds | 1 | 2008 | 30 | 0.320 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 44 | 0.310 |
Why?
| | Benzimidazoles | 1 | 2008 | 48 | 0.310 |
Why?
| | Male | 14 | 2024 | 25093 | 0.300 |
Why?
| | Thiazolidinediones | 1 | 2007 | 82 | 0.280 |
Why?
| | Coronary Restenosis | 1 | 2005 | 31 | 0.260 |
Why?
| | Hypoglycemic Agents | 1 | 2007 | 166 | 0.260 |
Why?
| | Clinical Trials as Topic | 4 | 2009 | 460 | 0.240 |
Why?
| | Smoking | 2 | 2018 | 510 | 0.230 |
Why?
| | Career Mobility | 1 | 2023 | 25 | 0.230 |
Why?
| | Policy | 1 | 2023 | 24 | 0.230 |
Why?
| | Organizational Policy | 1 | 2023 | 40 | 0.220 |
Why?
| | Academies and Institutes | 1 | 2023 | 18 | 0.220 |
Why?
| | Communication | 2 | 2022 | 244 | 0.220 |
Why?
| | Checklist | 1 | 2023 | 28 | 0.220 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2003 | 19 | 0.220 |
Why?
| | Research Personnel | 1 | 2023 | 62 | 0.210 |
Why?
| | Imidazoles | 1 | 2003 | 119 | 0.200 |
Why?
| | Schools | 1 | 2023 | 165 | 0.200 |
Why?
| | Angiotensin II | 1 | 2003 | 157 | 0.200 |
Why?
| | Heart Failure | 1 | 2007 | 454 | 0.200 |
Why?
| | Adult | 10 | 2023 | 13160 | 0.200 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2007 | 467 | 0.190 |
Why?
| | Itraconazole | 3 | 2008 | 40 | 0.190 |
Why?
| | Qualitative Research | 1 | 2023 | 325 | 0.190 |
Why?
| | Amiodarone | 1 | 2000 | 22 | 0.190 |
Why?
| | Cannabis | 1 | 2023 | 145 | 0.180 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2000 | 79 | 0.180 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 2 | 2012 | 36 | 0.180 |
Why?
| | Mentors | 1 | 2020 | 55 | 0.180 |
Why?
| | Heart Arrest | 2 | 2007 | 148 | 0.180 |
Why?
| | Self Report | 1 | 2020 | 192 | 0.160 |
Why?
| | Peer Review | 1 | 2018 | 9 | 0.160 |
Why?
| | Self-Assessment | 2 | 2016 | 46 | 0.150 |
Why?
| | Pilot Projects | 3 | 2009 | 699 | 0.150 |
Why?
| | Publishing | 1 | 2018 | 39 | 0.150 |
Why?
| | Motivation | 1 | 2020 | 273 | 0.150 |
Why?
| | Risk Factors | 4 | 2011 | 3619 | 0.150 |
Why?
| | Knowledge | 1 | 2017 | 28 | 0.150 |
Why?
| | Universities | 1 | 2017 | 156 | 0.140 |
Why?
| | Citrus paradisi | 2 | 2008 | 10 | 0.140 |
Why?
| | Food-Drug Interactions | 2 | 2008 | 14 | 0.140 |
Why?
| | Education, Pharmacy, Graduate | 1 | 2016 | 19 | 0.140 |
Why?
| | Tobacco Products | 1 | 2018 | 110 | 0.130 |
Why?
| | Pharmacists | 3 | 2023 | 144 | 0.130 |
Why?
| | Arkansas | 3 | 2023 | 1967 | 0.120 |
Why?
| | Middle Aged | 7 | 2023 | 11997 | 0.120 |
Why?
| | Young Adult | 3 | 2018 | 3936 | 0.120 |
Why?
| | Retrospective Studies | 2 | 2024 | 6117 | 0.110 |
Why?
| | Antifungal Agents | 2 | 2008 | 339 | 0.110 |
Why?
| | United States | 2 | 2021 | 4838 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2008 | 1374 | 0.100 |
Why?
| | Ticlopidine | 1 | 2012 | 55 | 0.100 |
Why?
| | Proton Pump Inhibitors | 1 | 2012 | 84 | 0.100 |
Why?
| | Life Style | 1 | 2011 | 140 | 0.090 |
Why?
| | Drug Interactions | 3 | 2012 | 206 | 0.090 |
Why?
| | Atenolol | 1 | 2009 | 13 | 0.090 |
Why?
| | Cerebrovascular Disorders | 1 | 2009 | 54 | 0.090 |
Why?
| | Health Behavior | 1 | 2011 | 251 | 0.090 |
Why?
| | Drug Tolerance | 1 | 2009 | 60 | 0.080 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2009 | 144 | 0.080 |
Why?
| | Problem-Based Learning | 1 | 2008 | 43 | 0.080 |
Why?
| | Beverages | 2 | 2008 | 68 | 0.080 |
Why?
| | Hirudins | 1 | 2007 | 16 | 0.070 |
Why?
| | Education, Medical, Undergraduate | 1 | 2008 | 82 | 0.070 |
Why?
| | Anaphylaxis | 1 | 2007 | 71 | 0.070 |
Why?
| | Edema | 1 | 2007 | 67 | 0.070 |
Why?
| | Drugs, Investigational | 1 | 2005 | 14 | 0.070 |
Why?
| | Students, Medical | 1 | 2008 | 159 | 0.070 |
Why?
| | Weight Gain | 1 | 2007 | 240 | 0.060 |
Why?
| | Insulin Resistance | 1 | 2007 | 264 | 0.060 |
Why?
| | Molecular Structure | 1 | 2005 | 297 | 0.060 |
Why?
| | Insulin | 1 | 2007 | 457 | 0.060 |
Why?
| | Risk Assessment | 1 | 2009 | 1262 | 0.060 |
Why?
| | beta-Cyclodextrins | 1 | 2004 | 16 | 0.060 |
Why?
| | Anticoagulants | 1 | 2007 | 254 | 0.060 |
Why?
| | Tachycardia, Ventricular | 2 | 2003 | 43 | 0.060 |
Why?
| | Antioxidants | 1 | 2005 | 248 | 0.060 |
Why?
| | Ephedra | 1 | 2003 | 8 | 0.060 |
Why?
| | Electrocardiography, Ambulatory | 1 | 2003 | 23 | 0.060 |
Why?
| | Phytotherapy | 1 | 2003 | 44 | 0.060 |
Why?
| | Plant Preparations | 1 | 2003 | 37 | 0.060 |
Why?
| | Receptors, Angiotensin | 1 | 2003 | 13 | 0.050 |
Why?
| | Prescription Fees | 1 | 2003 | 14 | 0.050 |
Why?
| | Hemostasis | 1 | 2003 | 55 | 0.050 |
Why?
| | Adolescent | 2 | 2018 | 6340 | 0.050 |
Why?
| | Practice Guidelines as Topic | 2 | 2007 | 448 | 0.050 |
Why?
| | Animals | 2 | 2009 | 13150 | 0.050 |
Why?
| | Aged, 80 and over | 1 | 2009 | 3125 | 0.050 |
Why?
| | Hepatocytes | 1 | 2003 | 181 | 0.050 |
Why?
| | Interleukin-6 | 1 | 2003 | 264 | 0.050 |
Why?
| | Ventricular Fibrillation | 1 | 2000 | 16 | 0.050 |
Why?
| | Attitude of Health Personnel | 1 | 2023 | 348 | 0.040 |
Why?
| | Aged | 2 | 2012 | 9272 | 0.040 |
Why?
| | Dietary Supplements | 1 | 2003 | 441 | 0.040 |
Why?
| | Attitude | 1 | 2019 | 69 | 0.040 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2000 | 133 | 0.040 |
Why?
| | Liver | 1 | 2003 | 1109 | 0.040 |
Why?
| | Risk | 1 | 2018 | 320 | 0.040 |
Why?
| | Pregnant Women | 1 | 2018 | 77 | 0.040 |
Why?
| | Nicotine | 1 | 2018 | 186 | 0.040 |
Why?
| | Societies, Pharmaceutical | 1 | 2016 | 12 | 0.030 |
Why?
| | Attitude to Health | 1 | 2018 | 191 | 0.030 |
Why?
| | Pharmaceutical Solutions | 2 | 2008 | 8 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 554 | 0.030 |
Why?
| | Child | 1 | 2008 | 6824 | 0.030 |
Why?
| | Accreditation | 1 | 2016 | 61 | 0.030 |
Why?
| | Area Under Curve | 2 | 2008 | 181 | 0.030 |
Why?
| | Cross-Over Studies | 2 | 2008 | 224 | 0.030 |
Why?
| | Time Factors | 2 | 2012 | 2912 | 0.030 |
Why?
| | Regression Analysis | 1 | 2012 | 395 | 0.020 |
Why?
| | Acute Coronary Syndrome | 1 | 2012 | 78 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2012 | 406 | 0.020 |
Why?
| | Pregnancy | 1 | 2018 | 2584 | 0.020 |
Why?
| | Cohort Studies | 1 | 2012 | 1422 | 0.020 |
Why?
| | Peer Group | 1 | 2008 | 54 | 0.020 |
Why?
| | Hospitalization | 1 | 2012 | 653 | 0.020 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2008 | 78 | 0.020 |
Why?
| | Risk Management | 1 | 2007 | 32 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2007 | 140 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2012 | 2179 | 0.020 |
Why?
| | Antibodies | 1 | 2007 | 155 | 0.020 |
Why?
| | Administration, Oral | 1 | 2008 | 423 | 0.020 |
Why?
| | Program Evaluation | 1 | 2008 | 349 | 0.020 |
Why?
| | Renal Insufficiency | 1 | 2007 | 109 | 0.020 |
Why?
| | Respiratory Insufficiency | 1 | 2007 | 112 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2007 | 486 | 0.020 |
Why?
| | Sex Factors | 1 | 2008 | 693 | 0.020 |
Why?
| | Clinical Competence | 1 | 2008 | 398 | 0.020 |
Why?
| | Cyclodextrins | 1 | 2004 | 17 | 0.010 |
Why?
| | Biological Availability | 1 | 2004 | 121 | 0.010 |
Why?
| | Ephedrine | 1 | 2003 | 21 | 0.010 |
Why?
| | Cimetidine | 1 | 2003 | 7 | 0.010 |
Why?
| | Receptors, Interleukin-6 | 1 | 2003 | 22 | 0.010 |
Why?
| | Diastole | 1 | 2003 | 69 | 0.010 |
Why?
| | Bradycardia | 1 | 2003 | 36 | 0.010 |
Why?
| | Systole | 1 | 2003 | 68 | 0.010 |
Why?
| | Reference Values | 1 | 2003 | 310 | 0.010 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2003 | 195 | 0.010 |
Why?
| | Patient Compliance | 1 | 2003 | 230 | 0.010 |
Why?
| | Heart Rate | 1 | 2003 | 292 | 0.010 |
Why?
| | Body Weight | 1 | 2003 | 513 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2003 | 391 | 0.010 |
Why?
| | Body Mass Index | 1 | 2003 | 652 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2003 | 1571 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2003 | 5138 | 0.010 |
Why?
|
|
Franks's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|